The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.
Phase: PHASE2 | Sponsor: University Medical Center Groningen | Compound: Psilocybin
- Status
- recruiting
- Institution
- University Medical Center Groningen
- Start date
- 2025-03-01
- End date
- 2028-01-01
- Registry ID
- NCT06782724
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.